Seacoast Bank's board declared a quarterly common dividend increase from $0.19 to $0.20 per share on October 22, 2026. The dividend will be paid on December 31, 2026, to shareholders recorded by December 15. Additionally, a $0.20 dividend was declared for each 1/1,000th share of its Series A Non-Voting Preferred Stock, payable on the same dates. As of June 30, 2026, Seacoast reported $21.4 billion in assets and operates 105 branches in Florida and Georgia.
Seacoast Banking dividend increase news provides context for readers. For those tracking major cryptocurrencies on Pluang, 43 of 50 rose and 6 fell as of Oct 24, 2026 01:31 WIB. Notable prices include BNB at Rp13.420.381 with a 2.28% rise, ETC at Rp141.197 up 2.26%, and XTZ at Rp5.556 gaining 2.21%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
